420 related articles for article (PubMed ID: 36581331)
1. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
2. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
4. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
[TBL] [Abstract][Full Text] [Related]
5. CD39 Identifies the CD4
Kortekaas KE; Santegoets SJ; Sturm G; Ehsan I; van Egmond SL; Finotello F; Trajanoski Z; Welters MJP; van Poelgeest MIE; van der Burg SH
Cancer Immunol Res; 2020 Oct; 8(10):1311-1321. PubMed ID: 32759363
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
Front Immunol; 2020; 11():340. PubMed ID: 32174925
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.
Eiva MA; Omran DK; Chacon JA; Powell DJ
Eur J Immunol; 2022 Jan; 52(1):96-108. PubMed ID: 34505280
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8+ T cells in Breast Cancer Implications for Adoptive Cell Therapy.
Gattas GI; Noël G; López F; González F; Prieto-Hinojosa A; Nava-Rivera LE; Willard-Gallo K; Argüello JR
Curr Pharm Biotechnol; 2023 Sep; ():. PubMed ID: 37680154
[TBL] [Abstract][Full Text] [Related]
9. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
[TBL] [Abstract][Full Text] [Related]
10. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J; van der Ploeg M; Ijsselsteijn ME; Ruano D; van der Breggen R; Duhen R; Peeters KCMJ; Fariña-Sarasqueta A; Verdegaal EME; van der Burg SH; Duhen T; de Miranda NFCC
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792124
[TBL] [Abstract][Full Text] [Related]
11. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
13. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1
Salas-Benito D; Conde E; Tamayo-Uria I; Mancheño U; Elizalde E; Garcia-Ros D; Aramendia JM; Muruzabal JC; Alcaide J; Guillen-Grima F; Minguez JA; Amores-Tirado J; Gonzalez-Martin A; Sarobe P; Lasarte JJ; Ponz-Sarvise M; De Andrea CE; Hervas-Stubbs S
Br J Cancer; 2021 Mar; 124(6):1138-1149. PubMed ID: 33402737
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CD103
Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
[TBL] [Abstract][Full Text] [Related]
16. Bystander CD4
Li S; Zhuang S; Heit A; Koo SL; Tan AC; Chow IT; Kwok WW; Tan IB; Tan DSW; Simoni Y; Newell EW
Oncoimmunology; 2022; 11(1):2012961. PubMed ID: 36524209
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
20. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]